Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses

Journal of Immunological Methods

Volumn 261, Issue 1-2, 2002, Pages 177-194

  Lim, Annick ^a   Baron, Véronique ^a   Ferradini, Laurent ^a   Bonneville, Marc ^b   Kourilsky, Philippe ^a   Pannetier, Christophe ^a,c  

^a INSTITUT PASTEUR   (France)

^b INSTITUT DE BIOLOGIE   (France)

^c Unite de Biologie Mole culaire du Ge ne chez les Extre mophiles   (France)

Author keywords

CD8+ T cell response; Human T cell receptor; Immunological monitoring; Quantitative PCR; T cell repertoire

Indexed keywords

CD8 ANTIGEN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; POLYMER;

ARTICLE; CELL SELECTION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; LYMPHOCYTE CLONE; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL PROTOCOLS; DNA, COMPLEMENTARY; GENE REARRANGEMENT, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOASSAY; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036499317     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00004-2     Document Type: Article

References (85)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus
3. A direct estimate of the human alphabeta T cell receptor diversity
4. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding
5. Identification of T cell ligands in a library of peptides covalently attached to HLA-DR4
6. Tumor antigens recognized by T cells
7. Generation of MHC-peptide tetramers: A new opportunity for dissecting T-cell immune responses
8. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires
9. Conservation of T cell receptor usage by HLA B27-restricted influenza-specific cytotoxic T lymphocytes suggests a general pattern for antigen-specific major histocompatibility complex class I-restricted responses
10. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
11. Size estimate of the alpha beta TCR repertoire of naive mouse splenocytes
12. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer
13. Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice
14. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen
15. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
16. In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8-subset
17. TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture
18. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires
19. Accessing complexity: The dynamics of virus-specific T cell responses
20. Interpreting cancer vaccine clinical trials
21. Diversity of the cytotoxic melanoma-specific immune response: Some CTL clones recognize autologous fresh tumor cells and not tumor cell lines
22. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
23. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
24. T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: Evidence for oligoclonal expansions in tumours and inflammatory diseases
25. Tumor-specific immune response: Current in vitro analyses may not reflect the in vivo immune status
26. Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts
27. An alternative approach to the assessment of gamma delta T-cell clonality in celiac disease intestinal lesions through cDNA heteroduplex analysis of T-cell receptor VJ junctions
28. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status
29. Antigen-specific therapy for autoimmune disease
30. Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects
31. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases
32. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
33. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
34. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
35. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
36. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
37. Frequency of clonally expanded T cells evaluated by PCR from a single cell
38. Rapid effector function in CD8+ memory T cells
39. A rapid method for semiquantitative analysis of the human V beta-repertoire using TaqManR PCR
40. Phage display of peptide/major histocompatibility complex
41. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
42. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
43. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment
44. Antigen triggering selectively increases TCRBV gene transcription
45. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor
46. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: Application to direct detection of their molecular imprint on the human peripheral T cell repertoire
47. Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy
48. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix
49. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
50. Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide
51. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
52. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
53. Design and evaluation of antigen-specific vaccination strategies against cancer
54. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
55. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments
56. T-cell repertoire diversity and clonal expansions in normal and clinical samples
57. The Immunoscope approach for the analysis of T cell repertoires
58. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
59. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
60. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide
61. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
62. Cytolytic T lymphocyte recognition of the immunodominant HLA-A * 0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
63. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
64. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
65. A new era for cancer immunotherapy based on the genes that encode cancer antigens
66. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
67. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
68. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: A four-centre comparative trial
69. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
70. Quantification of tumor-specific T lymphocytes with the ELISPOT assay
71. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients
72. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen melan-A/MART-1
73. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
74. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
75. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
76. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture
77. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
78. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A * 0201-associated tyrosinase peptide 368-376
79. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients
80. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma
81. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
82. Phage display of peptide/major histocompatibility class I complexes
83. An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations
84. The extent of the human germline T-cell receptor V beta gene segment repertoire
85. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy